Q-omics provides the consensus-scored EIF3LP2 profile across patient tissues and cancer cell-line models. EIF3LP2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, EIF3LP2 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, EIF3LP2 RNA expression shows 14,079 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BRCA as cancer lineages where EIF3LP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF3LP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF3LP2 survival associations across molecular data types. EIF3LP2 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF3LP2 RNA expression–survival associations across cancer types. High EIF3LP2 expression shows unfavorable associations in ACC and KIRP, but favorable associations in CESC, READ, BRCA and THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for EIF3LP2 RNA expression.
This table summarizes EIF3LP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for EIF3LP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF3LP2 shows lower tumor expression in BRCA and HNSC and higher tumor expression in COAD, KIRC, CHOL and LIHC. The BRCA box plot shows higher EIF3LP2 RNA expression in normal versus tumor tissue (log2 FC = −0.452, t-test p < 0.001).
This table shows molecular features associated with EIF3LP2 in patient tissues and cancer cell lines. In patient samples, EIF3LP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
